Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2018 ASCO Annual Meeting /
Aspirin combined with acid-reducing medicine offers moderate benefits in patients with Barrett’s oesophagus

1st - 5th Jun 2018

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.06.18
Views: 515
Rating:

Prof Janusz Jankowski - Royal College of Surgeons in Ireland, Dublin, Republic of Ireland

Prof Jankowski speaks with ecancer at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting about data from the ASPECT trial.

This was a phase III randomised trial in which Barrett’s oesophagus patients at a high risk of developing high-grade dysplasia or oesophageal cancer were treated with high dose proton pump inhibitors and aspirin, and Dr Jankowski estimates that this course of treatment prevented up to a quarter of cancers developing, and delayed its development by up to 2 years in other patients.

For more on these findings, watch him present the data in a press conference here, or read news coverage here.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.
 

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation